Abstract
1. The metabolic oxidation of debrisoquine (DB) was studied in 89 non-related Cuna Amerindian subjects. 2. Means and standard deviations for urinary recoveries of the intact drug and its 4-hydroxy metabolite (4-HD) were: %DB: 6.8 +/- 4.5; %4-HD: 16.0 +/- 9.1; %sum: 22.8 +/- 12.0. The log10 metabolic ratios for DB (LMRDB) were distributed within a single mode of insignificant skewness (-0.01, P greater than 0.10), which was unimodal (log kernel density and maximum likelihood methods) and normal (chi 2 = 22.5; d.f. = 15; P greater than 0.09; power of the test greater than 80%). 3. Therefore, no poor metabolizers (95% C.I.: 0.1%, 5.2%) were detected in the population sample studied.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arias T. D., Inaba T., Cooke R. G., Jorge L. F. A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbé Guaymí Amerindians: a case of genetic divergence with tentative phylogenetic time frame for the pathway. Clin Pharmacol Ther. 1988 Sep;44(3):343–352. doi: 10.1038/clpt.1988.160. [DOI] [PubMed] [Google Scholar]
- Arias T. D., Jorge L. F. An observation on the ethnic uniqueness of the debrisoquine and sparteine antimodes: a study in the Ngawbé Guaymí Amerindians of Panamá. Br J Clin Pharmacol. 1989 Oct;28(4):493–494. doi: 10.1111/j.1365-2125.1989.tb03532.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Arias T. D., Jorge L. F., Lee D., Barrantes R., Inaba T. The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers. Clin Pharmacol Ther. 1988 Apr;43(4):456–465. doi: 10.1038/clpt.1988.58. [DOI] [PubMed] [Google Scholar]
- Erdtmansky P., Goehl T. J. Gas-liquid chromatographic electron capture determination of some monosubstituted guanido-containing drugs. Anal Chem. 1975 Apr;47(4):750–752. doi: 10.1021/ac60354a049. [DOI] [PubMed] [Google Scholar]
- Jackson P. R., Tucker G. T., Woods H. F. Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots. Br J Clin Pharmacol. 1989 Dec;28(6):647–653. doi: 10.1111/j.1365-2125.1989.tb03557.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kalow W., Otton S. V., Kadar D., Endrenyi L., Inaba T. Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals. Can J Physiol Pharmacol. 1980 Sep;58(9):1142–1144. doi: 10.1139/y80-173. [DOI] [PubMed] [Google Scholar]
- Kalow W. Pharmacoanthropology: drug metabolism. Fed Proc. 1984 May 15;43(8):2326–2331. [PubMed] [Google Scholar]
- Lou Y. C., Ying L., Bertilsson L., Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet. 1987 Oct 10;2(8563):852–853. doi: 10.1016/s0140-6736(87)91034-8. [DOI] [PubMed] [Google Scholar]
- Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985 Oct;38(4):402–408. doi: 10.1038/clpt.1985.194. [DOI] [PubMed] [Google Scholar]
- Sommers D. K., Moncrieff J., Avenant J. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa. Hum Toxicol. 1988 May;7(3):273–276. doi: 10.1177/096032718800700308. [DOI] [PubMed] [Google Scholar]
- Steiner E., Bertilsson L., Säwe J., Bertling I., Sjöqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther. 1988 Oct;44(4):431–435. doi: 10.1038/clpt.1988.176. [DOI] [PubMed] [Google Scholar]